European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

[Business Wire] – Bristol-Myers Squibb Company today announced that the European Commission has approved ORENCIA® intravenous infusion and subcutaneous injection, in combination with methotrexate , for the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with MTX. http://finance.yahoo.com/news/european-commission-approves-bristol-myers-105900966.html